Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation.
ASAIO J
; 69(12): e474-e481, 2023 12 01.
Article
em En
| MEDLINE
| ID: mdl-37913503
ABSTRACT
This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO). We performed a single-center case series including adult patients >18 years old supported on either venovenous (VV) or venoarterial (VA) ECMO from January 1, 2014, to April 21, 2021. The primary outcome was hemostatic control defined as a composite of initial cessation of therapeutic interventions to mitigate bleeding or resumption of anticoagulation if previously held. Secondary outcomes included changes in transfusion requirements and lysis at 30-minute (LY30) values, venous thromboembolism (VTE) events, and seizures. In total, 47 patients were included for full analysis. There were 19 patients with surgical bleeds, 18 patients with medical bleeds, and 10 patients with multiple bleeds. Overall, initial hemostatic control was achieved in 79%, 67%, and 90% of patients, respectively. Pre- and post-TXA transfusion requirements were not significantly different ( p = 0.2), although the intraindividual change in median LY30 was -5.1% compared with baseline (95% confidence interval [CI], -12.4% to -1.5%, p = 0.005). The occurrence of VTE and seizures was relatively low and similar among patient bleeding groups. Tranexamic acid provided initial hemostatic control in roughly three quarters of patients with bleeding events on ECMO and side effects were infrequent.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácido Tranexâmico
/
Hemostáticos
/
Oxigenação por Membrana Extracorpórea
/
Tromboembolia Venosa
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article